Genentech’s Giredestrant Boosts PFS in ER+ Advanced Breast Cancer Genentech, a member of the Roche Group, announced encouraging results from the Phase III evERA study evaluating its investigational oral selective estrogen receptor degrader (SERD), giredestrant, in combination with everolimus. The…
Aptar Pharma, a global leader in drug delivery and active material science solutions, announced that its Unidose Liquid System (UDS) has been selected as the delivery technology for Enbumyst™ (Bumetanide Nasal Spray) 0.5 mg, recently approved by the U.S. Food…
VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies for neurodegenerative diseases, and Shape Therapeutics Inc. (“ShapeTX”), a leader in applying AI and RNA technologies to engineer next-generation genetic medicines, announced today that they have entered into an option and…
Immuto Scientific today announced the closing of an oversubscribed $8 million Seed 2 financing round alongside a new drug discovery collaboration with Daiichi Sankyo, a leading global pharmaceutical company. The funding and collaboration represent significant milestones for Immuto as it…
NucleoBio, Corp., a biotechnology innovator in precision oncology diagnostics, has announced a new strategic collaboration with PreCheck Health Services, a high-complexity CLIA-certified and CAP-accredited clinical laboratory. The partnership will support the clinical development and processing of Prostac™, NucleoBio’s proprietary diagnostic…
C-Further today announced that Great Ormond Street Hospital Charity (GOSH Charity), the UK’s largest dedicated charitable funder of child health research, has joined Cancer Research Horizons and LifeArc as a core partner in the international consortium. Together, the organizations will…
Geneos Therapeutics, a clinical-stage biotherapeutics company pioneering personalized immunotherapies for cancer (PICs), has announced remarkable clinical results from two long-term patients treated with its novel DNA-based therapy. One patient with glioblastoma multiforme (GBM), an aggressive brain cancer, and another with…
Almirall, S.A., a global biopharmaceutical company dedicated to medical dermatology, announced new long-term results from the POSITIVE study, presented as a late-breaker at the 34th Congress of the European Academy of Dermatology and Venereology (EADV 2025) in Paris. The POSITIVE…
Arlington Capital Partners a Washington, D.C.–based private investment firm with a focus on government-regulated industries, announced today that its portfolio company TEAM Technologies (“TEAM Tech”) has acquired TAG3 Engineering, LLC (“TAG3”). TEAM Tech is a leading provider of end-to-end outsourced…
Ollin Biosciences Launches with $100 Million Financing to Advance Next-Generation Ophthalmology Therapies Ollin Biosciences, Inc., a newly established clinical-stage biopharmaceutical company, announced its launch with an initial $100 million financing round led by ARCH Venture Partners, Mubadala Capital, and Monograph…
Prota Therapeutics Pty Ltd., a clinical-stage biotechnology company developing novel oral immunotherapy (OIT) treatments for food allergies, today announced that clinical research conducted in partnership with the Murdoch Children’s Research Institute (MCRI) was awarded a prestigious prize at the 2025…
Tasca Therapeutics Doses First Patient in Phase 1/2 Clinical Trial of CP-383 for Advanced Solid Tumors Tasca Therapeutics, a clinical-stage biotechnology company dedicated to developing targeted therapies for genetically defined cancers, announced today that the first patient has been dosed…